Clinical trial · Interventional
Germline Testing for Predisposition to Myeloid Malignancies
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
NCT07112287CI-TRIAL-00109390MyeloGenrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Genetic Predisposition to Disease | — | UNRESOLVED | — |
| Myeloid Hematological Malignancies | — | UNRESOLVED | — |
| Myeloid Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MyeloGen Gene Panel | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MyeloGen Germline Testing Group
- description
- Enrolled participants will complete: * Baseline visit with questionnaires, educational video, and punch skin biopsy * Negative genetic test results notification via mail * Positive genetic results will be followed up by an appointment with a genetic counselor or physician * Post-results questionnaires * Follow up via medical records for up to 2 years from time of study consent.
- interventionNames
- Device: MyeloGen Gene Panel
Primary outcomes (1)
- measure
- Successful Completion Rate
- timeFrame
- Up to 10 weeks
- description
- Successful completion rate of germline genetic testing will be defined as the proportion of participants who return genetic test results within 10 weeks of study consent, which would require there be no excessive delays in obtaining a skin biopsy.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age of 18 years or older * Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening. * Ability to understand and provide a signed and completed consent document in English. Exclusion Criteria: * Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team. * Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies
References
Publications (0)
Data not yet available
No reference posted for this study.